Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an assistant professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2. His clinical and preclinical research interests include the detection and characterization of advanced prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).

His research program has four aims: 1) To develop a dynamic imaging method of circulating tumor cells based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow to predict the patient’s response to systemic treatments, by analysing the circulating tumor cell responses to treatment in ex vivo culture. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells. 4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

L'Hôtel-Dieu de Québec
6, rue McMahon
Québec, Québec
Canada G1R 2J6
46 entries « 1 of 10 »

Richard PO, Lavallee LT, Pouliot F, Komisarenko M, Martin L, Latouff JB, Finelli A

Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses?

Journal Article

J Urol, 200 (4), pp. 731-736, 2018, ISSN: 0022-5347.

Abstract | Links:

Arsenault F, Beauregard JM, Pouliot F

Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.

Journal Article

Curr Opin Support Palliat Care, 12 (3), pp. 359-365, 2018, ISSN: 1751-4258.

Abstract | Links:

Saad F, Pouliot F, Danielson B, Catton C, Kapoor A

Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence.

Journal Article

Can Urol Assoc J, 12 (9), pp. E415-E420, 2018, ISSN: 1911-6470.

Abstract | Links:

Kassouf W, Monteiro LL, Drachenberg DE, Fairey AS, Finelli A, Kapoor A, Lattouf JB, Leveridge MJ, Power NE, Pouliot F, Rendon RA, Sabbagh R, So AI, Tanguay S, Breau RH

Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Journal Article

Can Urol Assoc J, 12 (8), pp. 231-238, 2018, ISSN: 1911-6470.

| Links:

Toren P, Hoffman A, Ding K, Joncas FH, Turcotte V, Caron P, Pouliot F, Fradet Y, Levesque E, Guillemette C, Klotz LH

Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial.

Journal Article

Clin Cancer Res, 2018, ISSN: 1078-0432.

Abstract | Links:

46 entries « 1 of 10 »

Active projects

  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Développement et utilisation de systèmes d’amplification transcriptionnelle multigéniques à des fins diagnostiques et thérapeutiques pour améliorer la prise en charge du cancer de la prostate., Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2017-07-01 to 2019-06-30

Recently finished projects

  • (FRSQ 74200 & 74200-2) Développement d'un modèle collaboratif de prise en charge des patients atteints d'un cancer de la prostate résistant à la castration., Subvention, Fondation du CHU de Québec, from 2016-08-03 to 2017-08-02
  • (FRSQ 75250) “Phosphoproteomic identification of predictive markers for enzalutamide resistance in castration prostate cancer" , Subvention, Canadian Urologic Oncology Group, from 2016-10-06 to 2017-10-05
  • (FRSQ 78541)CUA‐CUOG Astellas Research Grant Program, Subvention, Canadian Urologic Oncology Group, from 2017-06-07 to 2018-06-06
  • (FRSQ 78573) Recherche sur la technique de microscopie bioluminescence pour cancers prostatiques, Subvention, Fondation du CHU de Québec, from 2017-07-10 to 2018-07-09
  • Development of a urine-based prostate cancer cell bioluminescence imaging nanotechnology for single cell transcriptional characterization, Subvention, Société de recherche sur le cancer, Subvention de fonctionnement, from 2016-09-01 to 2018-08-31
  • Development of integrative multigenic molecular imaging methods to detect cancers in vivo and in vitro, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds des leaders John-R.-Evans (FLJR), from 2013-12-01 to 2016-12-31
  • Integrative prostate cancer detection and prognostication by molecular imaging, Subvention, Cancer de la prostate Canada, Subventions pour des Étoiles montantes (rising star), from 2014-01-01 to 2016-12-31
  • Novel immunotherapeutic approaches for localized prostate cancer., Subvention, Cancer de la prostate Canada, Subventions d'équipe Movember (Movember Discovery Grants), from 2013-07-01 to 2016-06-30
  • Programme de soutien aux nouveaux de la Faculté de médecine, Subvention, Université Laval - démarrage nouveau chercheur, Soutien facultaire aux jeunes chercheurs de la Faculté de médecine, from 2016-09-01 to 2017-08-31
  • PROPS: PET/MRI pre-Radiotherapy for Post-Prostatectomy Salvage., Subvention, Cancer de la prostate Canada, Subventions d'équipe Movember (Movember Discovery Grants), from 2014-01-01 to 2016-06-30
Data provided by the Université Laval research projects registery